The prospective 1-year EPIC study enrolled 341 patients with myelodysplastic syndromes (MDS); although baseline iron burden was >2500ng/mL, ∼50% were chelation-naïve. Overall median serum ferritin decreased significantly at 1 year (p=0.002). Decreases occurred irrespective of whether patients were chelation-naïve or previously chelated; changes were dependent on dose adjustments and ongoing iron intake. Sustained reductions in labile plasma iron were observed. Discontinuation rate (48.7%) and adverse event profile were consistent with previously reported deferasirox data in MDS. Alanine aminotransferase levels decreased significantly; change correlated significantly with reduction in serum ferritin (p<0.0001). This large dataset prospectively confirms the efficacy and well characterizes the safety profile of deferasirox in MDS.
Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes : results from the large 1-year EPIC study / N. Gattermann, C. Finelli, M. Della Porta, P. Fenaux, A. Ganser, A. Guerci-Bresler, M. Schmid, K. Taylor, D. Vassilieff, D. Habr, G. Domokos, B. Roubert, C. Rose, M.D. Cappellini, EPIC study investigators. - In: LEUKEMIA RESEARCH. - ISSN 0145-2126. - 34:9(2010 Sep), pp. 1143-1150.
Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes : results from the large 1-year EPIC study
M.D. CappelliniPenultimo
;
2010
Abstract
The prospective 1-year EPIC study enrolled 341 patients with myelodysplastic syndromes (MDS); although baseline iron burden was >2500ng/mL, ∼50% were chelation-naïve. Overall median serum ferritin decreased significantly at 1 year (p=0.002). Decreases occurred irrespective of whether patients were chelation-naïve or previously chelated; changes were dependent on dose adjustments and ongoing iron intake. Sustained reductions in labile plasma iron were observed. Discontinuation rate (48.7%) and adverse event profile were consistent with previously reported deferasirox data in MDS. Alanine aminotransferase levels decreased significantly; change correlated significantly with reduction in serum ferritin (p<0.0001). This large dataset prospectively confirms the efficacy and well characterizes the safety profile of deferasirox in MDS.Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.